Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06419374

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

Sponsor: 89bio, Inc.

Conditions Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Interventions Pegozafermin Placebo

Updated 19 times since 2024 Last updated: Mar 3, 2026 Started: May 24, 2024 Primary completion: Jun 30, 2028 Completion: Aug 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, this trial is actively recruiting participants. The trial is conducted by 89bio, Inc. and has accumulated 19 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

19 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3

▶ Show 14 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

89bio, Inc.

Data source: 89bio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Adelaide, Australia , Afula, Israel , Akron, United States , Albuquerque, United States , Almería, Spain , Amarillo, United States , Amiens, France , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) and 224 more locations